financetom
Business
financetom
/
Business
/
What's Going On With Better Choice Company Shares Thursday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Better Choice Company Shares Thursday?
Jun 20, 2024 11:38 AM

Better Choice Company Inc ( BTTR ) stock is trading higher Thursday after the company announced it reached a settlement with Alphia, ending litigation and resulting in Better Choice ( BTTR ) retiring its senior debt.

What To Know: Better Choice ( BTTR ), a pet health and wellness company, announced that it will retire its senior secured debt that includes $5 million in principal and $400,000 of payable-in-kind accrued interest.

In addition, the company will retire 335,640 warrants with a strike price of $11.44 per share that were set to expire in 2028.

Better Choice ( BTTR ) also announced that it entered into an agreement with Alphia to eliminate about $5 million of other indebtedness with savings up to $2.7 million if paid within 90 days.

See Also: 4 Medical Product Stocks to Buy From a Recovering Industry

How To Buy BTTR Stock

By now you're likely curious about how to participate in the market for Better Choice ( BTTR ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. In the case of Better Choice ( BTTR ), which is trading at $4.17 as of publishing time, $100 would buy you 23.98 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

BTTR Price Action: At the time of publication, Better Choice ( BTTR ) stock was trading 10.9% higher at $4.17, per data from Benzinga Pro.

Image: 5475664 from Pixabay.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise
Apr 5, 2024
10:20 AM EDT, 04/05/2024 (MT Newswires) -- Natera ( NTRA ) said Friday an analysis from a phase 3 study of muscle-invasive bladder cancer patients using its Signatera blood test yielded positive results. The company said the analysis of the study, which was presented at the European Association of Urology Congress in Paris, showed an overall survival rate of 100%...
eXp World Unit Appoints Leo Pareja Chief Executive Officer
eXp World Unit Appoints Leo Pareja Chief Executive Officer
Apr 5, 2024
10:19 AM EDT, 04/05/2024 (MT Newswires) -- eXp World Holdings ( EXPI ) unit eXp Realty on Friday named Leo Pareja as chief executive officer with immediate effect. Pareja succeeds Glenn Sanford, who stepped down to focus on his roles as founder, chairman, and CEO of eXp World ( EXPI ), the company said. Previously, Pareja was chief strategy officer...
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication
Apr 5, 2024
10:20 AM EDT, 04/05/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) and 2seventy bio (TSVT) said Friday that the US Food and Drug Administration has approved the expansion of the indication of the companies' myeloma treatment Abecma. The approval makes Abecma available to adult patients with triple class-exposed relapsed or refractory multiple myeloma following two or more previous lines...
L3Harris Sheds Antenna Business In Portfolio Refinement: Details
L3Harris Sheds Antenna Business In Portfolio Refinement: Details
Apr 5, 2024
L3Harris Technologies Inc ( LHX ) has signed a definitive agreement under which an affiliate of Kanders & Company, Inc. will acquire its antenna and related businesses for $200 million. The agreement aligns with L3Harris’ portfolio-shaping strategy for non-core assets. The transaction comprises $175 million of cash at closing and a $25 million seller note. The transaction proceeds are expected to be used consistent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved